Какова цена за Noxopharm Limited (NOX)

Цена за Noxopharm Limited (NOX) Это $0.0416118

Какова рыночная капитализация для Noxopharm Limited (NOX)

Рыночная капитализация для Noxopharm Limited (NOX) Это $12.78M

Прибыль Noxopharm Limited (NOX)

Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.

Год	Прибыль	Изменить
2026 (TTM)	$-4.82M	49.79%
2025	$-3.22M	-19.45%
2024	$-3.99M	-71.53%
2023	$-14.02M	-15.43%
2022	$-16.58M	136.55%
2021	$-7.01M	23.32%
2020	$-5.68M	-50.43%
2019	$-11.46M	-19.51%
2018	$-14.24M	507.24%
2017	$-2.35M	334.19%
2016	$-540.21K	0.00%

Год

Прибыль

Изменить

2026 (TTM)

$-4.82M

49.79%

2025

$-3.22M

-19.45%

2024

$-3.99M

-71.53%

2023

$-14.02M

-15.43%

2022

$-16.58M

136.55%

2021

$-7.01M

23.32%

2020

$-5.68M

-50.43%

2019

$-11.46M

-19.51%

2018

$-14.24M

507.24%

2017

$-2.35M

334.19%

2016

$-540.21K

0.00%

Компания	Прибыль	Разница в прибыли	Страна
Novo Nordisk A/S NVO.US	$20.46B	-424,852.71%	DK
Vertex Pharmaceuticals Incorporated VRTX.US	$4.64B	-96,506.98%	US
Regeneron Pharmaceuticals, Inc. REGN.US	$5.23B	-108,705.27%	US
UCB SA UCB.BR	$2.14B	-44,485.05%	BE
CSL Limited CSL.AX	$1.61B	-33,617.45%	AU

Компания

Прибыль

Разница в прибыли

Страна